Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model

Journal of Pediatric Surgery

Volumn 38, Issue 3, 2003, Pages 336-342

  Abramson, Lisa P ^a   Stellmach, Veronica ^a   Doll, Jennifer A ^a   Cornwell, Mona ^a   Arensman, Robert M ^a   Crawford, Susan E ^a   Ford, H ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

Anaplasia; Angiogenesis inhibitors; Pigment epithelium derived factor; Wilms' tumor; Xenograft

Indexed keywords

ANGIOGENESIS INHIBITOR; PIGMENT EPITHELIUM DERIVED FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; KIDNEY BLOOD VESSEL; MITOSIS; MOUSE; NEPHROBLASTOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0037371954     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1053/jpsu.2003.50104     Document Type: Conference Paper

References (25)

1. Neville HL. Ritchey ML: Wilms' tumor. Overview of National Wilms' Tumor Study Group results. Pediatr Urol Oncol 27:435-442, 2000
2. Zuppan CW. Beckwith JB, Luckey DW: Anaplasia in unilateral Wilms' tumor: A report from the National Wilms' Tumor Study Pathology Center. Hum Pathol 19:1199-1209, 1988
3. D'Angio GJ, Breslow N, Beckwith JB, et al: Treatment of Wilms' tumor: Results of the Third National Wilms' Tumor Study. Cancer 64:349-360, 1989
4. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71, 1992
5. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996
6. Bicknell R, Harris AL: Anticancer strategies involving the vasculature: Vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol 3:399-407, 1992
7. Boehm T, Folkman J, Browder T, et al: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407, 1997
8. Tombran-Tink J, Chader GG, Johnson LV: PEDF: A pigment epithelium- derived factor with potent neuronal differentiative activity. Exp Eye Res 53:411-414, 1991
9. Dawson DW, Volpert OV, Gillis P, et al: Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 285:245-248, 1999
10. Stellmach V, Crawford SE, Zhou W. et al: Prevention of ischemia induced retinopathy by the natural ocular anti-angiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 99:2593-2597, 2001
11. Rasmussen H, Chu KW, Campochiaro P, et al: Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF. 11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 12:2029-2032, 2001
12. Crawford SE, Stellmach V, Ranalli M, et al: Pigment epithelium-derived factor (PEDF) in neuroblastoma: A multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 114:4421-4428, 2001
13. Marvin MR, Kayton ML, O'Toole KM. et al: A metastasizing model of anaplastic human Wilms' tumor in the nude mouse. Eur J Pediatr Surg 8:295-298, 1998
14. Rowe DH, Kayton ML, O'Toole KM. et al: Pathological ingiogenesis in a murine model of human Wilms' tumor. J Pediatr Surg 34:676-679, 1999
15. Cha DR, Kim NH, Yoon JW, et al: Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 77: s104-112, 2000
16. Pilmore HL, Eris JM, Painter DM, et al: Vascular endothelial growth factor expression in human chronic renal allograft rejection. Transplantation 67:929-933, 1999
17. Lee JS, Kim HS, Jung JJ, et al: Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression. J Surg Oncol 77:55-60, 2001
18. Kayton ML, Rowe DH, O'Toole KM, et al: Metastasis correlates with production of vascular endothelial growth factor in a murine model of human Wilms' tumor. J Pediatr Surg 34:743-747, 1999
19. Skoldenberg EG, Christiansson J, Sandstedt B, et al: Angiogenesis and angiogenic growth factors in Wilms' tumor. J Urol 165: 2274-2279, 2001
20. Rowe DH, Huang J, Li J, et al: Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 35:30-32, 2000
21. Huang J, Moore J, Soffer S, et al: Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms' tumors. J Pediatr Surg 36:357-361, 2001
22. Spurbeck WW, Ng CYC, Zhou J, et al: Gene therapy-mediated expression of an angiogenesis inhibitor prevents orthotopic anaplastic Wilms' tumor xenograft growth. Presented at the 87th Clinical Congress of the American College of Surgeons, New Orleans, LA, Oct, 2001
23. Soffer SZ, Kim E, Moore JT, et al: Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms' tumor. J Pediatr Surg 36:1781-1784, 2001
24. Huang J, Soffer SZ, Kim ES, et al: p53 accumulation in favorable-histology Wilms' tumor is associated with angiogenesis and clinically aggressive disease. J Pediatr Surg 37:523-527, 2002
25. Dejong V, Degeroges A, Filleur S, et al: The Wilms' tumor gene product represses the transcription of thrombospondin-1 in response to overexpression of c-Jun. Oncogene 18:3143-3151, 1999